JMP Securities upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Perform to Market Outperform.

For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.

Shares of Vitae Pharmaceuticals closed at $4.11 yesterday.

Momentum Movers Upgrades

Vitae Pharmaceuticals (VTAE) PT Raised to $23 at WedbushMarch 18, 2016 6:42 AM Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PTMarch 17, 2016 6:27 AM Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic PatientsMarch 16, 2016 4:06 PM Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe PsoriasisMarch 16, 2016 4:05 PM Vitae Pharmaceuticals (VTAE) trading halted with news pendingMarch 16, 2016 4:01 PM